Citations

Showing 10 of 108152 citations.

Abstract 83: Blood-Based Circulating Cell-Free DNA Epigenetic Age Is Accelerated Among HIV-Infected Patients with Hepatocellular Carcinoma in Nigeria
Hawkins, Claudia , Okeke, Edith, Duguru, Mary, Odeghe, Emuobor , Qu, Yishu , Gursel, Demirkan, Abdulkareem, Fatimah, Kocherginsky, Masha , Sagay, Atiene S. , Zheng, Yinan , Lesi, Olufunmilayo , Kim, Kyeezu , Joyce, Brian , Wang, Jun , Roberts, Lewis R. , Akanmu, Alani , Imade, Godwin , Wei, Jian‐Jun , Kim, Kwang-Youn , Odukoya, Oluwakemi Ololade , Adeyemo, Wasiu Lanre , Wehbe, Firas , Achenbach, Chad J. , Ogunsola, Folasade Tolulope , Murphy, Robert C. , Hou, Lifang

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 1, 2021 | Volume: 30 | Issue: 7_Supplement | Pages: 83-83

10.1158/1538-7755.asgcr21-83 Get It

Abstract Purpose: Hepatocellular Carcinoma (HCC) is the leading cause of cancer-related mortality in Nigeria. HIV and viral hepatitis B (HBV) and C (HCV) co-infection are common in Nigeria that significantly accelerates liver disease progression including HCC. Aging-related DNA methylation signatures obtained in liquid biopsy, such as circulating cell-free DNA (ccfDNA) extracted from serum/plasma are promising minimally-invasive biomarkers that may inform HIV-associated HCC. We examined the epigenetic age acceleration (EpiAgeAccel) in ccfDNA in HCC patients with HIV. Methods: The study included three groups of participants: a) HIV positive with HCC (n=7); b) HIV positive and cancer-free (n=45); and c) HIV negative with HCC (n=33). Epigenetic age was estimated by Horvath's calculator using genome-wide ccfDNA methylation data profiled by Illumina EPIC array. EpiAgeAccel was computed as the residuals of a linear model of epigenetic age on chronological age, namely the unexplained portion of epigenetic age by chronological age. We used multiple linear regression to compare EpiAgeAccel between HIV/HCC groups, adjusting for sex, age, education, alcohol intake, and HBV/HCV infection. Results: Among HIV positive participants, there was a higher percentage of men (57% vs. 22%, p<0.001), HBV infection (29% vs. 11%, p=0.004), and HCV infection (57% vs. 2%, p<0.001) in the HCC group compared to the cancer-free group. EpiAgeAccel was 4.8 years higher in HIV positive patients with HCC compared to cancer-free HIV positives (p=0.02). Among HCC patients, EpiAgeAccel was 2.1 years higher in HIV positives compared to HIV negative but not statistically significant. Conclusion: Epigenetic age in ccfDNA is accelerated in HIV-positive HCC patients. EpiAgeAccel measured in ccfDNA may be developed into a surrogate biomarker for minimally invasive HCC detection among HIV-infected patients in low- and middle-income countries. Citation Format: Yinan Zheng, Claudia Hawkins, Edith Okeke, Mary Duguru, Emuobor Odeghe, Olufunmilayo Lesi, Yishu Qu, Kyeezu Kim, Brian Joyce, Jun Wang, Lewis Roberts, Demirkan Gursel, Abdulkareem Fatimah, Alani Akanmu, Godwin Imade, Jian-Jun Wei, Masha Kocherginsky, Kwang-Youn Kim, Oluwakemi Odukoya, Wasiu Adeyemo, Firas Wehbe, Chad Achenbach, Atiene Sagay, Folasade Ogunsola, Robert Murphy, Lifang Hou. Blood-Based Circulating Cell-Free DNA Epigenetic Age Is Accelerated Among HIV-Infected Patients with Hepatocellular Carcinoma in Nigeria [abstract]. In: Proceedings of the 9th Annual Symposium on Global Cancer Research; Global Cancer Research and Control: Looking Back and Charting a Path Forward; 2021 Mar 10-11. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2021;30(7 Suppl):Abstract nr 83.
Introduction. Pineal region tumors
Boop, Frederick A. , Bruce, Jeffrey N. , Türe, Uğur , Daniels, David J.

Mayo Clinic

Neurosurgical Focus: Video | July 1, 2021 | Volume: 5 | Issue: 1 | Pages: V1

10.3171/2021.4.focvid2174 Get It

Outcomes of operatively treated interprosthetic femoral fractures
Tibbo, Meagan E. , Limberg, Afton K. , Huang, Phil, Perry, Kevin I. , Berry, Daniel J. , Gausden, Elizabeth B. , Yuan, Brandon J. , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | July 1, 2021 | Volume: 103-B | Issue: 7 Supple B | Pages: 122-128

10.1302/0301-620x.103b7.bjj-2020-2275.r1 | PMID 34192901 Get It

AimsThe prevalence of ipsilateral total hip arthroplasty (THA) and total knee arthroplasty (TKA) is rising in concert with life expectancy, putting more patients at risk for interprosthetic femur fractures (IPFFs). Our study aimed to assess treatment methodologies, implant survivorship, and IPFF clinical outcomes.MethodsA total of 76 patients treated for an IPFF from February 1985 to April 2018 were reviewed. Prior to fracture, at the hip/knee sites respectively, 46 femora had primary/primary, 21 had revision/primary, three had primary/revision, and six had revision/revision components. Mean age and BMI were 74 years (33 to 99) and 30 kg/m2(21 to 46), respectively. Mean follow-up after fracture treatment was seven years (2 to 24).ResultsOverall, 59 fractures were classified as Vancouver C (Unified Classification System (UCS) D), 17 were Vancouver B (UCS B). In total, 57 patients (75%) were treated with open reduction and internal fixation (ORIF); three developed nonunion, three developed periprosthetic joint infection, and two developed aseptic loosening. In all, 18 patients (24%) underwent revision arthroplasty including 13 revision THAs, four distal femoral arthroplasties (DFAs), and one revision TKA: of these, one patient developed aseptic loosening and two developed nonunion. Survivorship free from any reoperation was 82% (95% confidence interval (CI) 66.9% to 90.6%) and 77% (95% CI 49.4% to 90.7%) in the ORIF and revision groups at two years, respectively. ORIF patients who went on to union tended to have stemmed knee components and greater mean interprosthetic distance (IPD = 189 mm (SD 73.6) vs 163 mm (SD 36.7); p = 0.546) than nonunited fractures. Patients who went on to nonunion in the revision arthroplasty group had higher medullary diameter: cortical width ratio (2.5 (SD 1.7) vs 1.3 (SD 0.3); p = 0.008) and lower IPD (36 mm (SD 30.6) vs 214 mm (SD 32.1); p < 0.001). At latest follow-up, 95% of patients (n = 72) were ambulatory.ConclusionInterprosthetic femur fractures are technically and biologically challenging cases. Individualized approaches to internal fixation versus revision arthroplasty led to an 81% (95% CI 68.3% to 88.6%) survivorship free from reoperation at two years with 95% of patients ambulatory. Continued improvements in management are warranted. Cite this article: Bone Joint J 2021;103-B(7 Supple B):122–128.
Is there a problem with modular dual mobility acetabular components in revision total hip arthroplasty at mid-term follow-up?
Hernandez, Nicholas M. , Wu, Christine J. , Lachiewicz, Paul F. , Ryan, Sean P. , Wellman, Samuel S. , Wu, Christine J , Ryan, Sean , Hinton, Zoe W.

Mayo Clinic

The Bone & Joint Journal | July 1, 2021 | Volume: 103-B | Issue: 7 Supple B | Pages: 66-72

10.1302/0301-620x.103b7.bjj-2020-2015.r1 | PMID 34192910 Get It

Aims Modular dual mobility (MDM) acetabular components are often used with the aim of reducing the risk of dislocation in revision total hip arthroplasty (THA). There is, however, little information in the literature about its use in this context. The aim of this study, therefore, was to evaluate the outcomes in a cohort of patients in whom MDM components were used at revision THA, with a mean follow-up of more than five years. Methods Using the database of a single academic centre, 126 revision THAs in 117 patients using a single design of an MDM acetabular component were retrospectively reviewed. A total of 94 revision THAs in 88 patients with a mean follow-up of 5.5 years were included in the study. Survivorship was analyzed with the endpoints of dislocation, reoperation for dislocation, acetabular revision for aseptic loosening, and acetabular revision for any reason. The secondary endpoints were surgical complications and the radiological outcome. Results The overall rate of dislocation was 11%, with a six-year survival of 91%. Reoperation for dislocation was performed in seven patients (7%), with a six-year survival of 94%. The dislocations were early (at a mean of 33 days) in six patients, and late (at a mean of 4.3 years) in four patients. There were three intraprosthetic dissociations. An outer head diameter of ≥ 48 mm was associated with a lower risk of dislocation (p = 0.013). Lumbrosacral fusion was associated with increased dislocation (p = 0.004). Four revision THAs (4%) were further revised for aseptic acetabular loosening, and severe bone loss (Paprosky III) at the time of the initial revision was significantly associated with further revision for aseptic acetabular loosening (p = 0.008). Fourteen acetabular components (15%) were re-revised for infection, and a pre-revision diagnosis of reimplantation after periprosthetic joint infection (PJI) was associated with subsequent PJI (p < 0.001). Two THAs had visible metallic changes on the backside of the cobalt chromium liner. Conclusion When using this MDM component in revision THA, at a mean follow-up of 5.5 years, there was a higher rate of dislocation (11%) than previously reported. The size of the outer bearing was related to the risk of dislocation. There was a low rate of aseptic acetabular loosening. Longer follow-up of this MDM component and evaluation of other designs are warranted. Cite this article: Bone Joint J 2021;103-B(7 Supple B):66–72.
Protons versus photons for the treatment of chordoma
Sayed, Iman El, Trifiletti, Daniel M, Lehrer, Eric J, Showalter, Timothy N, Dutta, Sunil W, Lehrer, Eric J. , Sayed, Iman El, Trifiletti, Daniel M, Showalter, Timothy N, Dutta, Sunil W

Mayo Clinic

Cochrane Database of Systematic Reviews | July 1, 2021 | Volume: 2021 | Issue: 7 | Pages: No page available

10.1002/14651858.cd013224.pub2 | PMID 34196007 Get It

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
Vreeland, Timothy J. , Hale, Diane F. , McCarthy, Patrick M. , Hickerson, Annelies T. , Park, Hyohyun, Sloan, Amanda JoEllen, Hyngstrom, John , Berger, Adam C. , Jakub, James W. , Shaheen, Montaser , Wagner, Thomas E., Faries, Mark B. , Peoples, George E. , Jakub, James W , McCarthy, Patrick , Adams, Alexandra M. , Chick, Robert C. , Clifton, Guy T. , O’Shea, Anne E. , Bohan, Phillip M. Kemp , Sussman, Jonathan

Mayo Clinic

Melanoma Research | July 1, 2021 | Volume: 31 | Issue: 4 | Pages: 378-388

10.1097/cmr.0000000000000758 | PMID 34193804 Get It

Immunotherapy has revolutionized the treatment of melanoma, yet survival remains poor for patients with metastatic disease. The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine has been shown to be safe adjuvant therapy for patients with resected stage III/IV melanoma who complete the primary vaccine series. Here, we describe an open-label trial of patients with metastatic melanoma treated with TLPLDC vaccine in addition to standard of care (SoC) therapies. The TLPLDC vaccine is created by loading autologous tumor lysate into yeast cell wall particles, which are phagocytosed by autologous dendritic cells ex vivo. Patients who recurred while enrolled in a phase IIb trial of adjuvant TLPLDC vaccine (crossover cohort) and patients with measurable metastatic melanoma cohort were offered TLPLDC vaccine along with SoC therapies. Tumor response was measured by RECIST 1.1 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated by intention-to-treat analysis. Fifty-four patients were enrolled (28 in crossover cohort; 26 in metastatic melanoma cohort). The vaccine was well-tolerated with no grade ≥3 adverse events when given with SoC therapies to include checkpoint inhibitors, BRAF/MEK inhibitors, tyrosine kinase inhibitors, intralesional therapy and/or radiation. In the crossover arm, OS was 76.5% and PFS was 57.1% (median follow-up of 13.9 months). In the metastatic melanoma arm, OS was 85.7% and PFS was 52.2% (median follow-up 8.5 months). The TLPLDC vaccine is well-tolerated and safe in combination with SoC therapies. Future trials will determine the efficacy of TLPLDC in combination with SoC therapies in metastatic melanoma.
Chicago Classification update (version 4.0): Technical review on diagnostic criteria for achalasia
Khan, Anzalee , Yadlapati, Rena , Gonlachanvit, Sutep , Katzka, David A. , Vaezi, Michael F. , Vela, Marcelo F. , Pandolfino, John E. , Khan, Abraham , Vela, Marcelo, Park, Moo In

Mayo Clinic

Neurogastroenterology & Motility | July 1, 2021 | Volume: 33 | Issue: 7 | Pages: No page available

10.1111/nmo.14182 | PMID 34190376 Get It

Abstract The recommended diagnostic criteria for achalasia have been recently updated by Chicago Classification version 4.0 (CCv4.0), the widely accepted classification scheme for esophageal motility disorders using metrics from high‐resolution manometry (HRM). CCv4.0 continued upon prior versions by subtyping achalasia into type I, type II, and type III on HRM. The achalasia subgroup of the CCv4.0 Working Group developed both conclusive and inconclusive statements for the HRM diagnoses of achalasia subtypes. Conclusive achalasia on HRM is defined as an abnormal median integrated relaxation pressure (IRP) in the primary position of wet swallows along with 100% failed peristalsis, with type I achalasia having 100% failed peristalsis without panesophageal pressurization (PEP), type II achalasia with PEP in at least 20% of swallows, and type III achalasia having at least 20% of swallows premature with no appreciable peristalsis. An inconclusive HRM diagnosis of achalasia can arise when there is an integrated relaxation pressure (IRP) that is borderline or at the upper limit of normal in at least one position, there is an abnormal IRP in both positions but evidence of peristalsis with PEP or premature swallows, or there is peristalsis in the secondary position after apparent achalasia in the primary position. In patients with dysphagia and an inconclusive HRM diagnosis of achalasia, supportive testing beyond HRM such as a timed barium esophagram (TBE) for functional lumen imaging probe (FLIP) is recommended. The review recommends a diagnostic algorithm for achalasia, discusses therapeutic options for the disease, and outlines future needs on this topic.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
Zhou, Zheng , Nath, Rajneesh , Černý, Jan , Wang, Hai-Lin, Zhang, Mei-Jie , Abdel‐Azim, Hisham , Agrawal, Vaibhav , Ahmed, Gulrayz , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Battiwalla, Minocher, Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Choe, Hannah , Copelan, Edward A. , Damlaj, Moussab , DeFilipp, Zachariah , Farhadfar, Nosha , Foran, James M. , Freytes, César O. , Gul, Zartash , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Hossain, Nasheed , Inamoto, Yoshihiro , Isola, Luis , Jain, Tania , Kamble, Rammurti T., Khan, Muhammad , Kharfan‐Dabaja, Mohamed A. , Kekre, Natasha , Khera, Nandita , Litzow, Mark R. , Liu, Hongtao , Marks, David I. , Martino, Rodrigo , Mathews, Vikram , Mishra, Asmita , Murthy, Hemant S. , Nagler, Arnon , Nakamura, Ryotaro , Nathan, Sunita , Olin, Rebecca L. , Palmisiano, Neil , Patnaik, Mrinal M. , Pawarode, Attaphol , Politikos, Ioannis , Rizzieri, David A. , Seo, Sachiko , Shah, Nirav N. , Uy, Geoffrey L. , Verdonck, Leo F. , Wang, Youjin , Weisdorf, Daniel J. , Wirk, Baldeep , Saber, Wael , Hashmi, Shahrukh, Jain, Tania , Murthy, Hemant S , Weisdorf, Dan , Martino, Rodrigo , Liu, Hongtao , Mathews, Vikram , Uy, Geoffrey , Ahmed, Gulrayz , Zhang, Mei‐Jie , Alkhateeb, Hassan B. , Assal, Amer , Bacher, Ulrike , Bajel, Ashish R. , Bashir, Qaiser , Battiwalla, Minocher, Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Lima, Marcos de , Díaz, Miguel Ángel , Gerds, Aaron T. , Gergis, Usama , Grunwald, Michael R. , Hamadani, Mehdi , Hertzberg, Mark , Kebriaei, Partow , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Olsson, Richard F. , Patel, Sagar S. , Perales, Miguel‐Angel , Politikos, Ioannis , Popat, Uday R , Sandmaier, Brenda M , Savani, Bipin N. , Valcárcel, David , Waller, Edmund K. , Wong, Eric Y.L. , Yared, Jean A.

Mayo Clinic

Blood Advances | July 1, 2021 | Volume: 4 | Issue: 13 | Pages: 3180-3190

10.1182/bloodadvances.2019001266 | PMID 32663298 Get It

Abstract There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P &lt; .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P &lt; .001). Long-term relapse was lower with FM (HR = 0.65, P &lt; .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM.
Ulnar Artery Access: A Nontraditional Access Site for Diagnostic Cerebral Angiography and Neurointervention: 2-Dimensional Operative Video
Dossani, Rimal H., Cappuzzo, Justin M. , Sonig, Ashish , Almayman, Faisal, Siddiqui, Adnan H. , Davies, Jason M. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan A. , Davies, Jason M , Siddiqui, Adnan H , Schirmer, Clemens M , Waqas, Muhammad , Levy, Elad I. , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Tawk, Rabih G. , Thomas, Ajith J

Mayo Clinic

Operative Neurosurgery | June 30, 2021 | Volume: 21 | Issue: 4 | Pages: E350-E352

10.1093/ons/opab221 | PMID 34195817 Get It

Abstract Transfemoral access has long been the main access site for cerebral angiography and neurointerventional procedures. Radial access is accepted as an alternative to the traditional transfemoral approach. Ulnar access may be undertaken if the radial artery is occluded or small caliber, or when radial artery preservation is needed. The safety and feasibility of ulnar access for neuroangiographic procedures has been demonstrated. 1-3 In this operative video, we demonstrate ulnar artery access in a patient in whom radial artery preservation was desired. We further elaborate on the technical nuances of this access. This nontraditional access site offers the same advantages as radial access, avoiding the need to switch to femoral artery access. A preoperative Allen's test is not necessary. Ultrasound imaging is used to aid in the identification and successful puncture of the ulnar artery. A medial to lateral approach for ulnar artery puncture is advised to avoid injury to the ulnar nerve. Careful application of wrist closure bands avoids hematoma accumulation. The patient gave informed consent for the procedure and video recording. Institutional review board approval was deemed unnecessary. Video. © University at Buffalo, May 2021. Used with permission.
First, do no harm
Hayes, Sharonne N. , Hayes, Sharonne N

Mayo Clinic

European Heart Journal | June 30, 2021 | Volume: 42 | Issue: 33 | Pages: 3172-3174

10.1093/eurheartj/ehab442 | PMID 34355759 Get It